Ahn Sowoon, Byun Sung Hye, Park Kibum, Ha Jong Lin, Kwon Byeonghun, Kim Jong Chan
Department of Anesthesiology and Pain Medicine, CHA Bundang Medical Center, CHA University, 59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-712, South Korea.
Department of Anesthesiology and Pain Medicine, School of Medicine, Catholic University of Daegu, Daegu, South Korea.
Can J Anaesth. 2016 Mar;63(3):283-9. doi: 10.1007/s12630-015-0510-0. Epub 2015 Oct 16.
The purpose of the current study was to evaluate the effects of pregabalin administration as an adjunct to fentanyl-based intravenous patient-controlled analgesia on opioid consumption and postoperative pain following arthroscopic shoulder surgery.
In this randomized controlled trial, 60 adult patients undergoing arthroscopic shoulder surgery were randomly assigned to receive either pregabalin 150 mg (Pregabalin group, n = 30) or placebo (Control group, n = 30) one hour before anesthetic induction. The primary outcome was the cumulative amount of fentanyl consumption during 48 hr postoperatively. Secondary outcomes were pain intensity, the number of rescue analgesics administered, and adverse effects related to the analgesic regimen, which were serially assessed during 48 hr postoperatively.
The cumulative fentanyl consumption during 48 hr postoperatively was significantly lower in the Pregabalin group than in the Control group ([1,126.0 (283.6) μg vs 1,641.4 (320.3) μg, respectively; mean difference, 515.4 μg; 95% confidence interval [CI], 359.0 to 671.8; P = < 0.001). Numeric rating scores for pain (0 to 10) were significantly lower in the Pregabalin group at six hours (mean difference, 2.9; 95% CI, 1.8 to 4.0), 24 hr (mean difference, 2.9; 95% CI, 1.9 to 3.8), and 48 hr (mean difference, 1.5; 95% CI, 0.6 to 2.3). The incidence of adverse effects related to the analgesic regimens, including nausea, sedation, and dizziness, were similar between the two groups.
A preoperative dose of pregabalin 150 mg administered before arthroscopic shoulder surgery resulted in significant analgesic efficacy for 48 hr in terms of opioid-sparing effect and improved pain intensity scores without influencing complications. This trial was registered at: http://cris.nih.go.kr , number CT0000578.
本研究旨在评估加巴喷丁作为芬太尼静脉自控镇痛辅助用药对肩关节镜手术后阿片类药物用量及术后疼痛的影响。
在这项随机对照试验中,60例接受肩关节镜手术的成年患者在麻醉诱导前1小时被随机分为两组,分别接受150毫克加巴喷丁(加巴喷丁组,n = 30)或安慰剂(对照组,n = 30)。主要结局指标为术后48小时内芬太尼的累计用量。次要结局指标包括疼痛强度、补救镇痛药的使用次数以及与镇痛方案相关的不良反应,这些指标在术后48小时内进行连续评估。
加巴喷丁组术后48小时内芬太尼的累计用量显著低于对照组(分别为[1,126.0(283.6)微克对1,641.4(320.3)微克];平均差值为515.4微克;95%置信区间[CI]为359.0至671.8;P = < 0.001)。加巴喷丁组在术后6小时(平均差值为2.9;95%CI为1.8至4.0)、24小时(平均差值为2.9;95%CI为1.9至3.8)和48小时(平均差值为1.5;95%CI为0.6至2.3)的疼痛数字评分(0至10分)显著更低。两组与镇痛方案相关的不良反应发生率,包括恶心、镇静和头晕,相似。
肩关节镜手术前给予150毫克加巴喷丁的术前剂量在48小时内具有显著的镇痛效果,可减少阿片类药物用量并改善疼痛强度评分,且不影响并发症。本试验已在以下网址注册:http://cris.nih.go.kr ,注册号CT0000578。